View Archive

Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Genomic Health, Inc., Gilead Sciences, Inc., Merck & Co., Inc., and Sanofi Genzyme.

School of Breast Oncology® Live Video Webcast: Clinical Updates From Chicago

School of Breast Oncology® Live Video Webcast: Clinical Updates From Chicago

Thursday, August 26, 2021

Live, Interactive Webcast!

7:00 PM to 9:00 PM EDT

This program has been rescheduled for August 26th from 7:00 to 9:00pm EDT. Please take the opportunity to register NOW and learn about the latest clinical updates in Breast Cancer with Dr. O'Shaughnessy and a panel of SOBO® faculty


Clinical trial data first presented at annual major oncology meetings can often lead to practice-changing results that impact optimal treatment of patients with breast cancer. The data can range from high-profile phase 3 trial results and guidance on the efficacy of treatment in specific patient subsets to impact of genomic assays or the promise of emerging novel agents. Unfortunately, many community oncologists are unable to attend these meetings, and they need another means to stay abreast of the latest information to provide cutting-edge care to their patients.

The School of Breast Oncology® Live Video Webcast: Clinical Updates From Chicago is an interactive program featuring leading experts in the field of breast cancer who will provide a comprehensive overview of noteworthy data presented at the international society meeting held virtually from Chicago in June 2021. The expert panel will discuss and debate the clinical implications and applications of these data and the future direction of breast cancer management. This webcast is an extension of the annual School of Breast Oncology®, and it provides an additional forum for clinicians to keep pace with rapidly emerging data and advancing treatment paradigms in breast cancer.

Benefits of Attending

  • Review clinical evidence supporting novel treatment options for early-stage breast cancer
  • Ask experts how they manage patients with hormone receptor–positive (HR+), HER2-negative breast cancer
  • Discover emerging treatment regimens for patients with triple-negative breast cancer
  • Determine how to sequence recently approved HER2-targeted therapies into current treatment paradigms for advanced breast cancer
  • Gain insights into applying the latest data for locoregional control, including surgery and radiation, for patients with breast cancer

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Genomic Health, Inc., Gilead Sciences, Inc., Merck & Co., Inc., and Sanofi Genzyme.

Target Audience

This activity is directed toward medical oncologists who treat patients with breast cancer. Fellows, nurses, nurse practitioners, physician assistants, and other health care professionals involved in the management of breast cancer will also be invited to participate.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Explain key efficacy and safety outcomes from recent clinical trials conducted among patients with breast cancer
  • Consider the relevance of landmark clinical trial findings in the context of how this evidence can be practically incorporated into evolving breast cancer treatment paradigms
  • Discuss ongoing clinical trials designed to answer important clinical questions in the field of breast cancer treatment

Hot Topics

  • Long-term results with immunotherapy for early-stage triple-negative breast cancer
  • Updated survival with CDK4/6 inhibitors for patients with HR+, HER2- advanced breast cancer
  • Prevalence of HER2 low expression in breast cancer subtypes
  • Identification of patients with early-stage invasive breast cancer who may omit adjuvant radiotherapy after breast-conserving surgery

Program Chair

Joyce O'Shaughnessy, MD
Joyce O'Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Baylor University Medical Center
Texas Oncology
Chair, Breast Cancer Research Program
The US Oncology Network
Dallas, TX


2 Ways to Register
  1. Online: click here.
  2. Phone: Please call (888) 949-0045 or (609) 378-3701.
Physicians' Education Resource®
2 Clarke Drive
Suite 110
Cranbury, NJ 08512
Registration Fee - Free

For registration assistance, please email info@gotoper.com, or call (888) 949-0045 or (609) 378-3701.

Physicians' Education Resource®, LLC reserves the exclusive rights to all recordings or reproductions of the conference and supporting materials. Unauthorized recording, by any means, is expressly prohibited.  This includes, but is not limited to, recording of presentations or reproductions of supporting audio/visual materials, exhibits, and other supporting Continuing Education materials.

Meeting information is accurate at the time of posting.


You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information

Registration Information

Professional Information


Calendar of Events
Filter By